

*New Developments in the Treatment of Hypertension:  
What the HOT Study Means to JNC-VI*

Proceedings in this Special Report supplement to *The American Journal of Managed Care* are based on presentations, roundtable discussions, and question-and-answer sessions that took place in Boston, Massachusetts, on August 1, 1998.

---

**SYMPOSIUM PANEL AND FACULTY**

*Chairs*

**Gary Gerstenblith, MD**  
Professor of Medicine  
Johns Hopkins University School of Medicine  
Director of Clinical Trials  
Cardiology Division  
Johns Hopkins Hospital  
Baltimore, Maryland

**Steven Schulman, MD**  
Associate Professor  
Johns Hopkins University School of Medicine  
Director of the Coronary Care Unit  
Johns Hopkins Hospital  
Baltimore, Maryland

*Panel Members*

**Stephen Brunton, MD**  
Executive Vice President  
Education and Scientific Affairs  
Clinical Communications, Inc.  
Greenwich, Connecticut

**Michael Cabana, PhD**  
Robert Wood Johnson Clinical Scholars Program  
Johns Hopkins University  
School of Public Health  
Baltimore, Maryland

**Dominic Hodgkin, PhD**  
Senior Research Associate  
The Heller School  
Brandeis University  
Waltham, Massachusetts

**Robert P. Jacobs, MD, MBA**  
Vice President of Clinical Affairs  
University MSO  
New York University  
New York, New York

**Franz H. Messerli, MD**  
Medical Director  
Division of Research  
Alton Ochsner Medical Foundation  
Ochsner Clinic Section on Hypertension  
New Orleans, Louisiana

**Donald S. Shepard, PhD**  
Research Professor  
The Heller School  
Brandeis University  
Waltham, Massachusetts

**Stephen L. Wagner, PhD**  
Administrator  
The Sanger Clinic, PA  
Charlotte, North Carolina

**Dee Whittlesey, MD**  
Medical Director  
Blue Cross/Blue Shield of Texas  
Richardson, Texas

**Marcus Wilson, PharmD**  
President and Chief Executive Officer  
HealthCore, Inc.  
Newark, Delaware

---

## DISCLOSURE STATEMENT

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations to disclose any real or apparent conflicts of interest.

These participants have declared the following affiliations with corporate organizations.

- **Stephen Brunton, MD**  
*Lecture Support From:*  
Glaxo Wellcome  
Schering  
Knoll  
Janssen  
McNeil
- **Gary Gerstenblith, MD**  
*Grant/Research Support From:*  
Hoechst Marion Roussel  
Rhone-Poulenc Rorer  
*Lecture Support From:*  
Rhone-Poulenc Rorer  
Pfizer
- **Robert P. Jacobs, MD, MBA**  
*Advisor To:*  
Franklin Health Inc.
- **Franz H. Messerli, MD**  
*Lecture Support From:*  
Eli Lilly  
Lederle  
Bristol-Myers Squibb  
Searle  
Astra  
Pfizer  
Hoechst Marion Roussel  
Novartis  
Knoll  
Merck
- **Donald S. Shepard, PhD**  
Schneider (USA), Inc.
- **Dee Whittlesey, MD**  
*Advisor To:*  
Glaxo Wellcome  
Wyeth-Ayerst  
Sepracor
- **Marcus Wilson, PharmD**  
*Research/Grant Support From:*  
Novartis  
Glaxo Wellcome  
Pfizer  
Parke-Davis  
SmithKline Beecham  
Searle  
Janssen  
*Lecture Support From:*  
Novartis  
Glaxo Wellcome  
Pfizer  
Parke-Davis  
*Advisor To:*  
Parke-Davis

The participants listed below declare no financial arrangements or affiliations with any corporate organization.

- **Michael Cabana, PhD**
- **Dominic Hodgkin, PhD**
- **Steven Schulman, MD**
- **Stephen L. Wagner, PhD**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Old Bridge, New Jersey.